TomoTherapy(R) Cancer Treatment Technology Debuts in Switzerland

  
    
  
  
    
      TomoTherapy Incorporated (NASDAQ: 
      TTPY) announced today that the University 
      Hospital of Lausanne (CHUV) has begun treating patients with the 
      TomoTherapy® Hi-Art® treatment 
      system, the first to be installed in Switzerland.
    
    
      “We are pleased to work with the CHUV to make 
      this new weapon in the fight against cancer available to Swiss patients,” 
      said Rik Van den Neste, M.D., director of European sales for 
      TomoTherapy. “By implementing the TomoTherapy 
      platform, the CHUV demonstrates its leadership and commitment to 
      providing access to new strategies for care.”
    
    
      The CHUV ranks 14th among 400 institutions 
      affiliated with the European Organisation 
      for Research and Treatment of Cancer (EORTC), which aims to reduce 
      the time lapse between the discovery of new technologies and the 
      implementation of their therapeutic benefit for patients with cancer. 
      The Hospital provides holistic care for a wide range of cancer patients 
      and looks forward to strengthening this approach with the unique 
      capabilities of the Hi-Art treatment system.
    
    
      Said Professor René-Olivier Mirimanoff, M.D., 
      head of the Radio-Oncology department, “TomoTherapy 
      helps us better target the tumour to be irradiated and preserve healthy 
      tissue located in the vicinity. Integrated CT imaging allows for the 
      scanning of patients before each treatment, which helps ensure proper 
      positioning.”
    
    
      Dr Raphaël Moeckli, Ph.D., head physicist, 
      added, “The system’s 
      delivery pattern makes it possible to ‘paint’ 
      the dose onto the tumour volume, from 360 degrees. These features open 
      new possibilities for minimizing the side effects of treatment, and for 
      treating types of cancer that were previously difficult to irradiate 
      because of nearby critical structures.”
    
    
      The Radio-Oncology Department, managed by the CHUV, recently hosted a 
      ceremony to introduce this state-of-the-art technology that integrates 
      CT image guidance and helical intensity-modulated radiation therapy for 
      greater accuracy and precision in the treatment of cancer. The event 
      included a scientific symposium attended by radiation oncologists, 
      medical physicists and therapists from across Switzerland and a public 
      conference attended by more than 100 local journalists and patient group 
      members.
    
    
      About the CHUV
    
    
      CHUV is one of the 5 major university hospitals in Switzerland. It 
      provides from primary to tertiary care in all domains of medicine, and 
      one of its major focuses is cancer. Many doctors and scientists are 
      involved in basic, translational and clinical research in cancer 
      medicine, which contributes to its international visibility. A number of 
      clinicians are currently involved in national and international 
      cooperative cancer research groups, including SAKK, EORTC, and hold 
      officer’s positions or have a leading role as 
      principal investigators of international trials. The department of 
      Radiation Oncology has an active role and has contributed to a number of 
      major international studies in various fields of oncology and has a 
      leading position in Switzerland
    
    
      About TomoTherapy Incorporated
    
    
      TomoTherapy Incorporated has developed, manufactures and sells the 
      TomoTherapy® Hi-Art® 
      treatment system, an advanced radiation therapy system for the treatment 
      of a wide variety of cancers. The Hi-Art treatment system 
      combines integrated CT imaging with conformal radiation therapy to 
      deliver sophisticated radiation treatments with speed and precision 
      while reducing radiation exposure to surrounding healthy tissue. The 
      company completed its initial public offering in May 2007 and its stock 
      is traded on the NASDAQ Global Market under the symbol TTPY. To learn 
      more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.
    
    
      ©2007 TomoTherapy Incorporated. All rights 
      reserved. TomoTherapy, the TomoTherapy logo and Hi-Art are among 
      trademarks, service marks or registered trademarks of TomoTherapy 
      Incorporated.